Sunshine Biopharma
SBFM | NASDAQ
$2.55
-$0.15 (-5.56%)
At close: Nov 16, 2026, 3:59 PM ET
$2.55
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:53 PM ET
-5.56%
(1D)No price chart data available for 1D timeframe.
Rating
42.5
-10.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #462/1021 (Top 45%)
Key Statistics
Market Data
Market Cap $5.42M
1D Range
2.55 2.63
52W Range
2.55 306.00
Valuation (TTM)
PE -0.01
PB 0.19
EV/EBITDA 1.55
Valuation (NTM)
Forward PE 33.18
Forward PEG 0.00
Price Target $0.00
Cash Flow
FCF Yield -96.4%
SBC Adj. FCF Yield -97.7%
SBC Impact -1.4%
Margins
Gross Margin 29.9%
Operating Margin -16.8%
FCF Margin -14.8%
Growth (CAGR)
Revenue 3Y | 5Y 20.2% |
190.4%
Dil EPS 3Y | 5Y 140.1% |
74.1%
FCF 3Y | 5Y 45.2% |
-4.0%
Returns
ROA -18.2%
ROE -24.5%
ROIC -20.4%
Financial Health
Net Cash
$14.62M
Current Ratio 6.47
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. ...
Sector Healthcare
Employees 50
IPO Date Feb 15, 2022
Website www.sunshinebiopharma.com
Fiscal Year January - December
Latest News
2 months ago · zacks.com
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should KnowSunshine Biopharma, Inc. (SBFM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$5.2
Miss -52.94%
YoY:
-173.68% REV
$9.44M
Miss -1.64%
YoY:
+0.27%Next Earnings
Apr 2, 2027
EPS Est
Pro
Rev Est
Pro
Add to Watchlist
Select watchlists to add or remove SBFM